Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program
- 18 August 2009
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 53 (4) , 594-598
Abstract
Background: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2‐dependent adult cancer cell lines and that has clinical efficacy against ErbB2‐overexpressing breast cancer.Methods: Lapatinib was tested against the cell lines of the PPTP in vitro panel at concentrations ranging from 1.0 nM to 10.0 µM. Lapatinib was tested against the xenografts of the PPTP in vivo panels using a twice‐daily oral administration schedule for 6 weeks (5 days on, 2 days off) at a dose of 160 mg/kg (320 mg/kg/day). Lapatinib pharmacokinetic parameters were determined in scid−/− mice.Results: The median IC50 value for lapatinib against the entire PPTP cell line panel was 6.84 µM (range, 2.08 to >10.0 µM). Lapatinib was well tolerated in vivo, with toxicity in only 1.5% of the treated animals. Lapatinib induced significant differences in EFS distribution compared to controls in 1 of 41 xenografts tested. No objective responses were observed in any of the solid tumor panels or in the ALL panel. Lapatinib systemic exposure was consistent with previously observed values.Conclusions: Lapatinib has little activity against the xenografts of the PPTP's in vivo panel, and its in vitro activity occurs at concentrations above those associated with specific EGFR/ErbB2 inhibition. These results likely reflect lack of ErbB2 overexpression in the models studied and suggest that adult and pediatric cancers may fundamentally differ in the applicability of EGFR family members as therapeutic targets. Pediatr Blood Cancer 2009;53:594–598.Keywords
Funding Information
- National Cancer Institute (NO1-CM-42216, CA21765, CA108786)
This publication has 23 references indexed in Scilit:
- Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium StudyJournal of Clinical Oncology, 2010
- Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing programPediatric Blood & Cancer, 2007
- Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell linesCell Proliferation, 2007
- Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cellsBiochemical and Biophysical Research Communications, 2007
- Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumorsMolecular Cancer Therapeutics, 2007
- A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinationsMolecular Cancer Therapeutics, 2007
- Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung CancerDrugs, 2007
- Evaluation of the Antitumor Efficacy, Pharmacokinetics, and Pharmacodynamics of the Histone Deacetylase Inhibitor Depsipeptide in Childhood Cancer Models In vivoClinical Cancer Research, 2006
- ERBB2 in Pediatric Cancer: Innocent Until Proven GuiltyThe Oncologist, 2005
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989